/IMMP
IMMP Stock - Immutep Limited
Healthcare|BiotechnologyNASDAQ
$2.63+0.38%
+$0.01 (+0.38%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+45.6%upside
Target: $3.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMMP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.60 – $2.66
TARGET (TP)$3.83
STOP LOSS$2.42
RISK/REWARD1:5.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.84
52W High$3.53
52W Low$1.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.04M | $3.84M | $3.51M | $170,369 | $3.86M |
| Gross Profit | $-56,366,759 | $-37,704,847 | $1.44M | $-1,893,106 | $-13,373,974 |
| Gross Margin | -1117.6% | -981.4% | 41.2% | -1111.2% | -346.2% |
| Operating Income | $-126,421,795 | $-88,104,186 | $-77,688,492 | $-33,937,554 | $-31,676,793 |
| Net Income | $-61,434,165 | $-42,716,625 | $-39,896,348 | $-32,210,826 | $-29,902,624 |
| Net Margin | -1218.0% | -1111.9% | -1138.0% | -18906.5% | -774.1% |
| EPS | $-0.42 | $-0.36 | $-0.44 | $-0.37 | $-0.49 |
Company Overview
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 223.2% Upside
Now
$7
Low
$9
Average
$10
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 17th 2024 | CapitalOne | Initiation | Overweight | $10 |
| August 3rd 2023 | Robert W. Baird | Initiation | Outperform | $7 |
Earnings History & Surprises
IMMPBeat Rate
82%
Last 11 quarters
Avg Surprise
+69.0%
EPS vs Estimate
Beats / Misses
9/2
Last 12 quarters
Latest EPS
$-0.18
Q3 2025
EPS Surprise History
Q1 22
+94.0%
$-0.01vs$-0.23
Q3 22
No data
Q1 23
+80.8%
$-0.02vs$-0.08
Q3 23
+84.8%
$-0.01vs$-0.09
Q2 24
+86.1%
$-0.01vs$-0.09
Q3 24
+86.1%
$-0.01vs$-0.08
Q1 25
+88.7%
$-0.01vs$-0.08
Q3 25
-44.0%
$-0.18vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | $-0.12 | $-0.18 | -44.0% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.08 | $-0.01 | +88.7% | ✓ BEAT |
Q3 2024 | Aug 30, 2024 | $-0.08 | $-0.01 | +86.1% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-0.09 | $-0.01 | +86.1% | ✓ BEAT |
Q3 2023 | Sep 28, 2023 | $-0.09 | $-0.01 | +84.8% | ✓ BEAT |
Q1 2023 | Feb 24, 2023 | $-0.08 | $-0.02 | +80.8% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | — | $-0.01 | — | — |
Q1 2022 | Feb 22, 2022 | $-0.23 | $-0.01 | +94.0% | ✓ BEAT |
Q3 2021 | Aug 30, 2021 | $-0.38 | $-0.01 | +97.4% | ✓ BEAT |
Q1 2021 | Feb 23, 2021 | $-0.36 | $-0.38 | -5.6% | ✗ MISS |
Q3 2020 | Aug 25, 2020 | — | $-0.01 | — | — |
Q1 2020 | Feb 24, 2020 | $-0.19 | $-0.01 | +94.4% | ✓ BEAT |
Q3 2019 | Aug 20, 2019 | — | $-0.02 | — | — |
Q1 2019 | Feb 27, 2019 | — | $-0.02 | — | — |
Q3 2018 | Aug 21, 2018 | — | $-0.02 | — | — |
Q1 2018 | Feb 22, 2018 | — | $-0.01 | — | — |
Q3 2017 | Aug 28, 2017 | — | $-0.07 | — | — |
Q1 2017 | Feb 24, 2017 | $-0.36 | $-0.01 | +96.2% | ✓ BEAT |
Q3 2016 | Aug 31, 2016 | — | $-0.51 | — | — |
Latest News
Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer
📈 PositiveBenzinga•Dec 16, 2025, 01:02 PM
Immutep shares are trading higher after the company and Dr. Reddy's announced that their respective wholly-owned subsidiaries have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China.
📈 PositiveBenzinga•Dec 8, 2025, 04:17 PM•Also:
Immutep And Dr. Reddy's Enter Collaboration And Exclusive Licensing Agreement For commercialization Of Eftilagimod Alfa In All Countries Outside North America, Europe, Japan And Greater China; Immutep To Receive $20M Upfront Payment And Milestones Up To $349.5M Plus Royalties
📈 PositiveBenzinga•Dec 8, 2025, 01:06 PM•Also:
Immutep Data From EFTISARC-NEO Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA Exceeds Prespecified Level Of Pathologic Response Rates, Reaches Median 51.5% Tumor Hyalinization/Fibrosis
📈 PositiveBenzinga•Nov 13, 2025, 01:02 PM
Immutep Receives ~A$4.6 Million R&D Tax Incentive Payment In Cash From French Government Under Crédit d'Impôt Recherche Scheme
📈 PositiveBenzinga•Nov 3, 2025, 01:08 PM
Immutep's Reports EFTISARC-NEO Phase II Trial Data; The Investigator-Initiated Phase II Study Evaluating Eftilagimod Alfa With Radiotherapy Plus KEYTRUDA The Neoadjuvant Setting For Resectable Soft Tissue Sarcoma Met Its Primary Endpoint
📈 PositiveBenzinga•Oct 20, 2025, 12:10 PM
Immutep Announces U.S. FDA Has Provided Feedback Confirming Successful Completion Of Project Optimus Requirements And Agreement On 30mg As The Optimal Biological Dose For Its Lead Immunotherapy Candidate, Eftilagimod Alfa
📈 PositiveBenzinga•Oct 13, 2025, 12:07 PM
Immutep Announces Its Global Phase III TACTI-004 Trial For Advanced Non-Small Cell Lung Cancer Has Surpassed Key Milestone With Over 170 Patients Enrolled And Randomized
📈 PositiveBenzinga•Oct 9, 2025, 12:07 PM
Immutep Initiates Phase II Trial Of Efti As Monotherapy And With Chemotherapy For Early-Stage HR+/HER2- Breast Cancer
📈 PositiveBenzinga•Sep 22, 2025, 12:17 PM
Immutep To Present Phase II EFTISARC-NEO Trial Data On Efti + KEYTRUDA Combo In Soft Tissue Sarcoma At CTOS 2025
➖ NeutralBenzinga•Sep 8, 2025, 12:12 PM
Frequently Asked Questions about IMMP
What is IMMP's current stock price?
Immutep Limited (IMMP) is currently trading at $2.63 per share. The stock has moved +0.38% today.
What is the analyst price target for IMMP?
The average analyst price target for IMMP is $3.83, based on 1 analyst.
What sector is Immutep Limited in?
Immutep Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMMP's market cap?
Immutep Limited has a market capitalization of $0.39 billion, making it a small-cap company.
Does IMMP pay dividends?
No, Immutep Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
CADL
Candel Therapeutics, Inc.
$5.57
Mkt Cap: $0.3B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
PRQR
ProQR Therapeutics N.V.
$2.21
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
Explore stocks similar to IMMP for comparison